



MESAS SPR

Mesas SPR

ACTA REUMATOL PORT. 2017;32:49-51 (SUP)

MESA SPR – NOVARTIS

“IL-17A INHIBITION - CHALLENGING THE TREATMENT PARADIGM IN SPA”

MODERADORES: Fernando Pimentel dos Santos e Carlos Vaz

- **THE IL-17A JOURNEY IN SPA: FROM THEORY TO PROOF-OF-CONCEPT**
Dhavalkumar Patel
- **SECUCINUMAB IN SPA: FROM PROOF-OF-CONCEPT TO CLINICAL PRACTICE**
Frank Behrens

MESA SPR – LILLY

MODERADOR: Maria José Santos

- **JAK/STAT PATHWAY INHIBITION. A NOVEL OPPORTUNITY IN RA MANAGEMENT**
José M. Alvaro-Gracia
- **BARICITINIB – UM NOVO PARADIGMA NA ABORDAGEM DA ARTRITE REUMATÓIDE**
Augusto Faustino

MESA SPR – SANOFI GENZYME

“TRENDS IN RHEUMATOID ARTHRITIS”

MODERADOR: João Eurico Fonseca

- **UNMET NEEDS IN RHEUMATOID ARTHRITIS**
Maria José Santos
- **UPCOMING THERAPEUTIC APPROACHES IN RA: EXAMPLES OF HEAD TO HEAD TRIALS**
Robert Landewé
- **THERAPEUTIC ALTERNATIVES FOR IL-6 BLOCKING IN RA: STATE OF THE ART OF SARILUMAB**
Blanca Hernandez-Cruz

MESA SPR – MSD

“GUIDELINES AND CLINICAL PRACTICE – AIMING AT THE BEST CARE”

MODERADOR: João Eurico Fonseca

- **EULAR 2016 RECOMMENDATIONS FOR RA & AXSPA MANAGEMENT**
Sofia Ramiro
- **AIMING AT THE BEST HEALTHCARE RESOURCES UTILIZATION**
Elsa Vieira de Sousa
- **PHYSICIAN AND PATIENT GAP**
Cátia Duarte

MESA SPR – PFIZER

“SIGNALING THE FUTURE IN RA MANAGEMENT”

MODERADOR: João Eurico Fonseca

- **UNMET NEEDS & JAK PATHWAYS**
Robert Landewé
- **FROM CLINICAL TRIALS TO REAL WORLD DATA**
Bernard Combe

MESA SPR – BIOGEN

“FROM THE BENCH TO THE BEDSIDE AND BEYOND – OPPORTUNITIES AND CHALLENGES USING ANTI-TNF BIOSIMILARS”

- **A BRIGHTER FUTURE? BIOSIMILARS SEEN AS AN ADDITIONAL CONTRIBUTION TO BETTER MEDICAL OUTCOMES AND MEDICAL RESEARCH**
João Eurico Fonseca
- **SCIENTIFIC/MEDICAL CHALLENGES – CURRENT SITUATION AND CHALLENGES THAT NEED TO BE ADDRESS FROM A CLINICAL PERSPECTIVE**
Maria Jose Cuadrado

- **HOW CAN BIOSIMILARS FULFIL ALL THEIR POTENTIAL IN THE TREATMENT TO IMPROVEMENT OF PATIENT'S LIVES?**

Filipe Araújo

MESA SPR – CELGENE

MODERADOR: Elsa Vieira de Sousa

- **PSA IMMUNOPATHOLOGY: DECODING THE COMPLEX INTERPLAY IN PSA**

Dennis McGonagle

- **PSA CLINICAL CHALLENGE: TREATING ITS COMPLEXITY WITH PDE4 INHIBITION. CLINICAL EXPERIENCE IN PSA WITH PDE4 INHIBITOR**

Jordi Gratacós